

RETINA 360 WORKBOOK



IN FOCUS: DIABETIC EYE DISEASE CLINICAL PEARLS

Fluid Tolerance With Diabetic Macular Edema

FACULTY



Priya S. Vakharia, MD

Program Chair

Retina Vitreous Associates of Florida
Palm Harbor and St. Petersburg, FL



Leanne Clevenger, MD

Assistant Professor of Ophthalmology
University of Kentucky
Lexington, KY

This activity is supported by an independent educational grant from Regeneron.

Fluid Tolerance With Diabetic Macular Edema

Priya S. Vakharia, MD, and Leanne Clevenger, MD

Watch Now: <https://evolvemeded.com/segment/29861/>


CASE HIGHLIGHTS

- The case involves a 69-year-old woman with a history of longstanding diabetes and diabetic macular edema (DME), presenting with 20/50 VA.
- Drs. Vakharia and Clevenger discuss the choice of anti-VEGF therapy, considering options like aflibercept, bevacizumab, and emerging second-generation agents.
- There is a shift toward greater tolerance of persistent fluid in DME treatment, with a focus on reducing treatment burden rather than strict drying of the macula.
- Potential biomarkers like hyperreflective foci are discussed as predictors of treatment response.
- The case highlights the ongoing evolution in DME management, with a balance between visual acuity improvement and durability of treatment effect.

NOTES

"It's going to be really exciting to see where we are as a field in 10 to 15 years and how the treatment paradigm is going to shift. Are we still going to be treating until dry? Are we going to tolerate more fluid? Or are things going to completely be different in 10 to 15 years?"

PRIYA S. VAKHARIA, MD



VIDEO CASE: PATIENT OCT AFTER THE THIRD DOSE OF AFLIBERCEPT 8 MG.

